The stock of Genprex Inc (GNPX) has seen a -1.83% decrease in the past week, with a -30.97% drop in the past month, and a 130.11% flourish in the past quarter. The volatility ratio for the week is 7.53%, and the volatility levels for the past 30 days are at 16.79% for GNPX. The simple moving average for the last 20 days is -16.06% for GNPX stock, with a simple moving average of -44.13% for the last 200 days.
Is It Worth Investing in Genprex Inc (NASDAQ: GNPX) Right Now?
The 36-month beta value for GNPX is at -1.38. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for GNPX is 7.98M, and currently, shorts hold a 4.29% of that float. The average trading volume for GNPX on December 06, 2024 was 9.51M shares.
GNPX) stock’s latest price update
Genprex Inc (NASDAQ: GNPX)’s stock price has decreased by -0.93 compared to its previous closing price of 1.08. However, the company has seen a -1.83% decrease in its stock price over the last five trading sessions. prnewswire.com reported 2024-11-20 that License includes Genprex’s Reqorsa® Gene Therapy in Combination with ALK-Inhibitors for the Potential Treatment of ALK-Positive Lung Cancer AUSTIN, Texas, Nov. 20, 2024 /PRNewswire/ — Genprex, Inc. (“Genprex” or the “Company”) (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced it has entered into an exclusive license agreement with the University of Michigan, granting Genprex a worldwide, exclusive license to the University’s patent rights relating toits lead drug candidate, Reqorsa® Gene Therapy (quaratusugene ozeplasmid), in combination with ALK-inhibitors for the potential treatment of ALK-EML4 positive translocated lung cancer. “We continue to bolster our intellectual property portfolio for REQORSA, understanding that our lead drug candidate may benefit patients with many types of cancers,” said Thomas Gallagher, Esq.
Analysts’ Opinion of GNPX
Many brokerage firms have already submitted their reports for GNPX stocks, with National Securities repeating the rating for GNPX by listing it as a “Buy.” The predicted price for GNPX in the upcoming period, according to National Securities is $7 based on the research report published on January 26, 2021 of the previous year 2021.
Noble Capital Markets, on the other hand, stated in their research note that they expect to see GNPX reach a price target of $5. The rating they have provided for GNPX stocks is “Outperform” according to the report published on April 29th, 2019.
GNPX Trading at -13.19% from the 50-Day Moving Average
After a stumble in the market that brought GNPX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -92.57% of loss for the given period.
Volatility was left at 16.79%, however, over the last 30 days, the volatility rate increased by 7.53%, as shares sank -38.46% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +197.57% upper at present.
During the last 5 trading sessions, GNPX fell by -4.59%, which changed the moving average for the period of 200-days by -76.36% in comparison to the 20-day moving average, which settled at $1.2732. In addition, Genprex Inc saw -88.37% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for GNPX
Current profitability levels for the company are sitting at:
- -985.8 for the present operating margin
- 0.64 for the gross margin
The net margin for Genprex Inc stands at -980.82. The total capital return value is set at -13.71. Equity return is now at value -325.11, with -221.01 for asset returns.
Currently, EBITDA for the company is -31.06 million with net debt to EBITDA at 0.07. When we switch over and look at the enterprise to sales, we see a ratio of 334.41. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.86.
Conclusion
In conclusion, Genprex Inc (GNPX) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
